Completed PHASE3 INTERVENTIONAL 2-arm NCT00461903

Efficacy of Perindopril to Prevent Recurrence of Atrial Fibrillation in Patients With Essential Hypertension (CTAF-2)

A Prospective, Randomized, Double-blind Placebo-controlled Study to Determine the Efficacy of 8 mg/Day Oral Perindopril to Prevent the Recurrence of Atrial Fibrillation in Patients With Essential Hypertension

Sponsor: Montreal Heart Institute

Conditions Atrial Fibrillation Essential Hypertension

Interventions Perindopril

Updated 6 times since 2017 Last updated: Feb 20, 2020 Started: Dec 31, 2007 Primary completion: Sep 30, 2015 Completion: Sep 30, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00461903, this PHASE3 trial focuses on Atrial Fibrillation and Essential Hypertension and remains completed. Sponsored by Montreal Heart Institute, it has been updated 6 times since 2007, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Mar 2020 — Jan 2021 [monthly]

Completed PHASE3
Jun 2018 — Mar 2020 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Dec 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Montreal Heart Institute
Servier

Data source: Montreal Heart Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Montreal, Canada